SCHEMBL23927859

SCHEMBL23927859

COc1ccc2c(CC(OC(=O)/C=C/C(=O)OC(Cc3c[nH]c4cc(OC)ccc34)N(C)C)N(C)C)c[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.52
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50
HTR2A P28223 2/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 4/20 0.46
HTR1A P08908 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ACHE P22303 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TUBB1 Q9H4B7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927939 0.91 HTR2B (0.55) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL8001578 0.78 HTR2A (0.57) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL7995675 0.78 HTR2A (0.57) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL7997990 0.78 HTR2A (0.57) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL25769074 0.76 HTR2A (0.65) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL8261028 0.76 MTNR1A (0.56) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL24328915 0.75 SMN1; SMN2 (0.60) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL24328257 0.75 MEN1 (0.58) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL28413745 0.75 SMN1; SMN2 (0.60) HTR6MTNR1AMTNR1BHTR2AKMT2A
SCHEMBL8869627 0.75 HTR2B (0.51) HTR6MTNR1AMTNR1BHTR2AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254640-B2 N-substituted indoles and other heterocycles for treating brain disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-22 US disclosed
US-20210332012-A1 N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254640-B2 N-substituted indoles and other heterocycles for treating brain disorders TPH2, AANAT, HTR2C HTR6 10/4885MTNR1A 61/4885MTNR1B 70/4885
US-20210332012-A1 N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS TPH2, AANAT, HTR2C HTR6 10/4885MTNR1A 61/4885MTNR1B 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.